Status:
COMPLETED
Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
OCD Institute
Mclean Hospital
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Memantine is a glutamate receptor antagonist that has been reported to reduce Obsessive-Compulsive Disorder (OCD) symptoms in case studies of treatment-resistant individuals. The investigators hypothe...
Eligibility Criteria
Inclusion
- Consecutive patients of IRT at the OCD Institute who agreed to augmentation with memantine.
- Consecutive patients of IRT at the OCD Institute who were not offered augmentation with memantine and who were matched according to OCD severity, gender, and psychosocial functioning.
Exclusion
- Subjects offered memantine augmentation who did not provide voluntary consent.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00869505
Start Date
March 1 2008
Last Update
March 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OCD Institute, McLean Hospital
Belmont, Massachusetts, United States, 02478